close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
The European Commission has authorized GSK’s HIV-focused unit ViiV Healthcare’s cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.
EUROPEAN COMMISSION CHIEF URSULA VON DER LEYEN ASSURES AID TO FLOOD-STRICKEN SLOVENIA DURING VISIT
Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 77.16 pounds, according to the company.
The GlaxoSmithKline logo is seen in this illustration, Aug. 10, 2022. (REUTERS/Dado Ruvic/Illustration/File Photo)
Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil.
CLICK HERE TO GET THE FOX NEWS APP
Columbia University recently confirmed a major cyberattack that compromised personal, financial and health-related information tied…
Rental car drivers are now turning to artificial intelligence to protect themselves from surprise damage…
IN TODAY’S NEWSLETTER: - Google CEO, major tech leaders join first lady Melania Trump at…
Thousands of people have had their sensitive personal information exposed in a data breach at…
Technology keeps changing the way we work, connect and even form relationships. Now it is…
Over a year ago, National Public Data (NPD) made headlines for one of the largest…